TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07091734: Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Sponsor: University of Michigan · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 32 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT07091734 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07091734 Rescue Dossier →